close
close

Iteos Therapeutics-Aktie erreicht 52-Wochen-Tief at 8.39 US-Dollar from Investing.com

Iteos Therapeutics-Aktie erreicht 52-Wochen-Tief at 8.39 US-Dollar from Investing.com

The Action of Iteos Therapeutics Inc. (NASDAQ: ITOS) has received a 52-Wochen-Tief and is trading at US$8.39. This young Kursstand marks a bedeuten decline for the biotechnology unternehmen, that is the Entwicklung of Krebs immunotherapies that have been specially developed. The year in which Iteos Therapeutics’ Aktienwert sank by 15.09%, investors’ reservations and the reformed market area for the biotech sector were more broadly mirrored. The road from the Unternehmens to die 52-Wochen-Tief is no longer focused on the sector of the new volatilität, which means that it navigates more complex Landschaft der Arzneimittelentwicklung and behördlichen Zulassungen.

In others, iTeos Therapeutics has reported widely reported ergebnisse aus seiner Phase-2-GALAXIES-Lung-201-Studie, the combination of Belrestotug and Dostarlimab with the treatment of PD-L1-hohem nicht-kleinzelligem Lungenkrebs dissected. The European Society for Medical Oncology conference has received a positive assessment from analysts. JPMorgan, Piper Sandler and HC Wainwright have made their “Overweight” and “Buy” investments for iTeos deeds, with Wells Fargo developing an “Overweight” initiate hat.

The US dollar reports net survival of US$1.07 pro-action for the first quarter of 2024, lowering net survival of US-dollar 0.98 pro-action. You can earn an amount of $1.1 million in dollars.

Among the young people working at iTeos Therapeutics Dr. David Feltquate has taken over as the new Chief Medical Officer. At the Jahresshauptversammlung der Aktionäre, two Class I Directors, Jill M. DeSimone and David K. Lee, were present. Deloitte Bedrijfsrevisoren / Réviseurs d’Entreprises BV/SRL works as an independent works council for the best business operations.

InvestingPro Insights

The latest share price of Iteos Therapeutics Inc. (NASDAQ: ITOS) is active during InvestingPro data, but a strong price increase of 41.45% in the three major currencies. Dieser Trend stimulates the article in one of the 52-Wochen-Tiefs überein. Moreover, investing more money as debt abroad ensured greater financial stability in the market turbulence.

Analysts can make a wise choice and conduct a study over time. If you are optimistic about not being able to make profitable profits in those years, you can get another InvestingPro-Tipp tip. If the accounting of the Unternehmens of 0.51 implies, the trading in the Verhältnis of the Powerswerten possible non-bewertet, was potentially a Silberstreif on the Horizon for wertorientierte Investors-darstellt.

If you make any of the following analyses, InvestingPro will allow you to use 7 different tips, which like some of the financial prosperity and market position of Iteos Therapeutics.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.